E W Cowen

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Eruptive linear papules on the abdomen of a woman with ascites
    Edward W Cowen
    Dermatology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Am Acad Dermatol 51:75-8. 2004
  2. ncbi Differentiation of tumour-stage mycosis fungoides, psoriasis vulgaris and normal controls in a pilot study using serum proteomic analysis
    E W Cowen
    Dermatology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Br J Dermatol 157:946-53. 2007
  3. ncbi Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole
    Edward W Cowen
    Dermatology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Am Acad Dermatol 62:31-7. 2010
  4. ncbi Epidermal growth factor receptor inhibitors: a new era of drug reactions in a new era of cancer therapy
    Edward W Cowen
    Dermatology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Am Acad Dermatol 56:514-7. 2007
  5. ncbi Voriconazole-induced phototoxicity masquerading as chronic graft-versus-host disease of the skin in allogeneic hematopoietic cell transplant recipients
    Asha R Patel
    Dermatology Branch, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
    Biol Blood Marrow Transplant 15:370-6. 2009
  6. ncbi Determinants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graft-versus-host disease (cGVHD)
    S A Mitchell
    Nursing Research, Clinical Center, National Institutes of Health, Bethesda, MD 20852, USA
    Bone Marrow Transplant 45:762-9. 2010
  7. ncbi Chronic granulomatous disease as a risk factor for autoimmune disease
    Suk See De Ravin
    National Institutes of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892 1456, USA
    J Allergy Clin Immunol 122:1097-103. 2008
  8. ncbi Dyskeratosis congenita: the first NIH clinical research workshop
    Sharon A Savage
    Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland 20892, USA
    Pediatr Blood Cancer 53:520-3. 2009
  9. ncbi Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report
    Steven Z Pavletic
    National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1203, USA
    Biol Blood Marrow Transplant 12:252-66. 2006
  10. ncbi Salivary gland involvement in chronic graft-versus-host disease: prevalence, clinical significance, and recommendations for evaluation
    Matin M Imanguli
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Biol Blood Marrow Transplant 16:1362-9. 2010

Detail Information

Publications24

  1. ncbi Eruptive linear papules on the abdomen of a woman with ascites
    Edward W Cowen
    Dermatology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Am Acad Dermatol 51:75-8. 2004
  2. ncbi Differentiation of tumour-stage mycosis fungoides, psoriasis vulgaris and normal controls in a pilot study using serum proteomic analysis
    E W Cowen
    Dermatology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Br J Dermatol 157:946-53. 2007
    ..The resultant 'proteomic signature' has been used to differentiate benign and malignant diseases, enable disease prognosis, and monitor response to therapy...
  3. ncbi Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole
    Edward W Cowen
    Dermatology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Am Acad Dermatol 62:31-7. 2010
    ..Voriconazole is a broad-spectrum antifungal agent associated with photosensitivity and accelerated photoaging. A possible link with aggressive squamous cell carcinoma (SCC) has also been reported...
  4. ncbi Epidermal growth factor receptor inhibitors: a new era of drug reactions in a new era of cancer therapy
    Edward W Cowen
    Dermatology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Am Acad Dermatol 56:514-7. 2007
  5. ncbi Voriconazole-induced phototoxicity masquerading as chronic graft-versus-host disease of the skin in allogeneic hematopoietic cell transplant recipients
    Asha R Patel
    Dermatology Branch, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
    Biol Blood Marrow Transplant 15:370-6. 2009
    ..A high index of suspicion for this adverse reaction in the post-alloHCT setting will prevent misdiagnosis and avoid inappropriate therapy for cGVHD...
  6. ncbi Determinants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graft-versus-host disease (cGVHD)
    S A Mitchell
    Nursing Research, Clinical Center, National Institutes of Health, Bethesda, MD 20852, USA
    Bone Marrow Transplant 45:762-9. 2010
    ..004). Results suggest two possible mechanisms underlying impaired functional performance in survivors with cGVHD and underscore the importance of testing interventions to enhance functional capacity and reduce symptom bother...
  7. ncbi Chronic granulomatous disease as a risk factor for autoimmune disease
    Suk See De Ravin
    National Institutes of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892 1456, USA
    J Allergy Clin Immunol 122:1097-103. 2008
    ..The presence and type of autoimmune disease have important treatment implications for patients with CGD...
  8. ncbi Dyskeratosis congenita: the first NIH clinical research workshop
    Sharon A Savage
    Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland 20892, USA
    Pediatr Blood Cancer 53:520-3. 2009
    ..dcoutreach.com/). Ongoing, open collaboration between the clinical, scientific, and family communities is required for continued improvement in our understanding of DC and the clinical consequences of telomeric defects...
  9. ncbi Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report
    Steven Z Pavletic
    National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1203, USA
    Biol Blood Marrow Transplant 12:252-66. 2006
    ..The proposed response criteria are based on current expert consensus opinion and are intended to improve consistency in the conduct and reporting of chronic GVHD trials, but their use remains to be demonstrated in practice...
  10. ncbi Salivary gland involvement in chronic graft-versus-host disease: prevalence, clinical significance, and recommendations for evaluation
    Matin M Imanguli
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Biol Blood Marrow Transplant 16:1362-9. 2010
    ..Formal evaluation of salivary function using standardized criteria is needed, and this could be incorporated as an outcome measure in clinical trials of cGVHD...
  11. ncbi Hypomorphic Rag mutations can cause destructive midline granulomatous disease
    Suk See De Ravin
    Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 116:1263-71. 2010
    ..This study was registered at www.clinicaltrials.gov as #NCT00128973...
  12. ncbi Oral chronic graft-vs.-host disease characterization using the NIH scale
    H Fassil
    Experimental Transplantation and Immunology Branch, National Cancer Institute, NIH, 10 Center Drive, Bethesda, MD 20892, USA
    J Dent Res 91:45S-51S. 2012
    ..We propose the use of >2 points on the NIH scale as a reproducible definition of clinically significant oral cGVHD, which may be useful in clinical settings or as eligibility criterion or as an endpoint in clinical trials...
  13. ncbi Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent
    Samer H Jaber
    Dermatology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892-1908, USA
    Arch Dermatol 142:166-72. 2006
    ..Specific features of skin eruption associated with anti-CTLA-4 resemble those described for maculopapular reactions to medications...
  14. ncbi Magnetic resonance imaging in sclerotic-type chronic graft-vs-host disease
    Jason Clark
    Dermatology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Arch Dermatol 145:918-22. 2009
    ....
  15. ncbi Localization of sclerotic-type chronic graft-vs-host disease to sites of skin injury: potential insight into the mechanism of isomorphic and isotopic responses
    Kathryn J Martires
    Dermatology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Dr, Bethesda, MD 20892, USA
    Arch Dermatol 147:1081-6. 2011
    ....
  16. ncbi Triad of severe abdominal pain, inappropriate antidiuretic hormone secretion, and disseminated varicella-zoster virus infection preceding cutaneous manifestations after hematopoietic stem cell transplantation: utility of PCR for early recognition and ther
    Rachel Rau
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1104, USA
    Pediatr Infect Dis J 27:265-8. 2008
    ..She was treated with acyclovir and subsequently developed VZV antigen-positive zoster. Detection of VZV DNA in blood may be useful for early diagnosis in immunocompromised hosts who present with zoster without skin lesions...
  17. ncbi Gynecomastia and mucosal lentigines in an 8-year-old boy
    Laura Winterfield
    Dermatology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892-1908, USA
    J Am Acad Dermatol 53:660-2. 2005
  18. ncbi Thrombocytopenia, multiple mucosal squamous cell carcinomas, and dyspigmentation
    Marisa Braun
    Dermatology Branch, Center for Cancer Research, Division of Cancer Epidemiology and Research, National Institutes of Health, Bethesda, Maryland, USA
    J Am Acad Dermatol 54:1056-9. 2006
  19. ncbi An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist
    Ivona Aksentijevich
    National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD 20892, USA
    N Engl J Med 360:2426-37. 2009
    ..We report a disorder caused by mutations of IL1RN, which encodes the interleukin-1-receptor antagonist, with prominent involvement of skin and bone...
  20. ncbi Multiple painful cutaneous nodules and renal mass
    Anne Rothman
    Dermatology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-1908, USA
    J Am Acad Dermatol 55:683-6. 2006
  21. ncbi National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report
    Alexandra H Filipovich
    Cincinnati Children s Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio 45229, USA
    Biol Blood Marrow Transplant 11:945-56. 2005
    ..It is currently recommended that systemic therapy be considered for patients who meet criteria for chronic GVHD of moderate to severe global severity...
  22. ncbi Proteomic patterns for classification of ovarian cancer and CTCL serum samples utilizing peak pairs indicative of post-translational modifications
    Chenwei Liu
    Clinical Proteomics Reference Laboratory, Gaithersburg, MD, USA
    Proteomics 7:4045-52. 2007
    ..This simple peak picking technique could be used to guide identification of important peak pairs involved in the disease process...
  23. ncbi Keratoacanthomas associated with sorafenib therapy
    Heidi H Kong
    J Am Acad Dermatol 56:171-2. 2007
  24. ncbi The isomorphic response in morphealike chronic graft-vs-host disease
    Asha R Patel
    Arch Dermatol 144:1229-31. 2008